

NEWS RELEASE

HYDERABAD, INDIA (8 June' 2021) -- SUVEN Pharmaceuticals Limited ("SPL", "Company") today announced audited financial results for the quarter and year ended 31 March' 2021. The audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 8 June' 2021 at Hyderabad.

Financial Snapshot

INR (Millions, except ratios and EPS)

	Quarter ended			Year ended	
	31-Mar-21	31-Dec-20	31-Mar-20	31-Mar-21	31-Mar-20
Revenue	2,624.63	2,797.76	1,901.05	10,239.56	8,519.07
EBITDA	969.91	1,421.77	819.16	4,547.59	3,997.60
EBITDA Margin	36.95%	50.82%	43.09%	44.41%	46.93%
EBIT	886.76	1,334.20	749.52	4,231.23	3,762.53
EBIT Margin	33.79%	47.69%	39.43%	41.32%	44.17%
Finance costs	18.70	19.10	65.12	91.44	186.62
Depreciation	83.15	87.58	69.64	316.36	235.07
Taxes	223.54	338.75	151.99	1,053.32	875.10
Taxes to PBT	25.75%	25.76%	22.21%	25.44%	24.47%
PAT (Standalone)	644.52	976.35	532.41	3,086.47	2,700.80
PAT Margin (Standalone)	24.56%	34.90%	28.01%	30.14%	31.70%
Associate Company	186.66	160.00	209.69	537.36	482.13
PAT (Consolidated)	831.16	1,136.25	741.82	3,623.42	3,170.02
PAT Margin (Consolidated)	31.67%	40.61%	39.02%	35.39%	37.21%
EPS (Standalone)	2.53	3.84	2.09	12.12	10.61
EPS (Consolidated)	3.27	4.46	2.91	14.23	12.45
Paid up share capital (Re.1/sh)	254.56	254.56	127.28	254.56	127.28

Growth Ratios

	Quarter ended 31 Mar 21 to 31 Dec 20	Quarter ended 31 Mar 21 to 31 Mar 20	Year ended 31 Mar 21 to 31 Mar 20
Growth in income	-6.19%	38.06%	20.20%
Growth in EBITDA	-31.78%	18.40%	13.76%
Growth in EBIT	-33.54%	18.31%	12.46%
Growth in PAT Standalone	-33.99%	21.06%	14.28%
Growth in PAT Consolidated	-26.85%	12.04%	14.30%

- The Company is focused on the business of Contract Development and Manufacturing Operations (CDMO).

Suven Pharmaceuticals Limited

2. The Board has recommended a Final Dividend of Re.1.00 per share of face value of Rs.1.00 each (100%) for approval of members in the ensuing AGM of the Company. With this the total dividend for the year ending March 2021 stood at Re.2.00 per share of face of value of Rs.1.00 each (200%).
3. The Board has allotted the Bonus shares at 1:1 ratio in its Board meeting held on 29 September' 2020. Accordingly, the number of shares increased from 12,72,82,478 to 25,45,64,956. In order to maintain uniformity and comparability the EPS of previous periods have been restated.
4. The COVID-19 did have some impact on the business and research operations in India starting March 2021 and continues to impact in terms of employee absenteeism (around 20%), adjustment of shifts due to lock down, material movements and increase in raw material and logistics cost due to shortage of oxygen. However, there was no major impact on our subsidiary, Suven Pharma, Inc., USA.

For more information, please visit: <http://www.suvenpharm.com>

Risk Statement:

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve number of risks and uncertainties. Although Suven Pharmaceuticals attempts to be accurate in making these statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven Pharmaceuticals may not undertake to update any forward-looking statements that may be made from time to time.

Suven Pharmaceuticals Limited